Department of Immunotechnology, Lund University, S-223 81 Lund, Sweden.
J Immunol. 2013 Jul 15;191(2):551-60. doi: 10.4049/jimmunol.1202051. Epub 2013 Jun 12.
Detailed understanding of how Abs of the IgE isotype interact with allergen at the onset of an allergic reaction is of great importance for deciphering mechanisms involved in the development of disease and may aid in the design of hypoallergenic variants. In this study, we have used a set of human monoclonal IgE Abs derived from the repertoires of allergic individuals, specific for the major timothy grass pollen allergen Phl p 1, to gain detailed information on the interaction between Abs and allergen. These allergen-specific IgE are to varying degrees cross-reactive toward both different allergen isoforms and various group 1 allergens originating from other grass species. The usage of human monoclonal IgE, as an alternative to polyclonal preparations or mouse Abs, allowed us to locate several important IgE-binding epitopes on the C-terminal domain of Phl p 1, all clustered to an IgE-binding "hot spot." By introducing three mutations in the IgE-binding area of the C-terminal domain we were able to significantly reduce its reactivity with serum IgE. In conclusion, our study shows the great potential of using human monoclonal IgE as a tool for studies of the molecular interactions taking place during allergic responses. Furthermore, we present a novel IgE-hyporeactive fragment with the potential to be used as a safer hypoallergenic alternative in specific immunotherapy than the pollen extracts used today.
详细了解 IgE 同种型的 Abs 如何在过敏反应发生时与过敏原相互作用,对于解析疾病发展过程中涉及的机制非常重要,并且可能有助于设计低变应原性变体。在这项研究中,我们使用了一组源自过敏个体的免疫球蛋白 E (IgE) 单克隆抗体,这些抗体特异性针对主要的 timothy 草花粉过敏原 Phl p 1,以获取关于 Abs 与过敏原相互作用的详细信息。这些过敏原特异性 IgE 对不同的过敏原同工型和来自其他草种的各种 1 组过敏原具有不同程度的交叉反应性。使用人类单克隆 IgE 替代多克隆制剂或小鼠 Abs,使我们能够定位 Phl p 1 C 末端结构域上的几个重要 IgE 结合表位,这些表位均聚集在 IgE 结合的“热点”上。通过在 C 末端结构域的 IgE 结合区域引入三个突变,我们能够显著降低其与血清 IgE 的反应性。总之,我们的研究表明,使用人类单克隆 IgE 作为研究过敏反应过程中分子相互作用的工具具有巨大的潜力。此外,我们提出了一种新型的 IgE 低反应性片段,有可能比目前使用的花粉提取物作为更安全的变应原性替代品,用于特异性免疫治疗。